231 related articles for article (PubMed ID: 26728480)
1. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
2. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
[TBL] [Abstract][Full Text] [Related]
3. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.
Koga N; Moriya F; Waki K; Yamada A; Itoh K; Noguchi M
Cancer Sci; 2017 Dec; 108(12):2326-2332. PubMed ID: 28898532
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
Shirahama T; Muroya D; Matsueda S; Yamada A; Shichijo S; Naito M; Yamashita T; Sakamoto S; Okuda K; Itoh K; Sasada T; Yutani S
Cancer Sci; 2017 May; 108(5):838-845. PubMed ID: 28188670
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
7. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
Noguchi M; Kakuma T; Uemura H; Nasu Y; Kumon H; Hirao Y; Moriya F; Suekane S; Matsuoka K; Komatsu N; Shichijo S; Yamada A; Itoh K
Cancer Immunol Immunother; 2010 Jul; 59(7):1001-9. PubMed ID: 20146063
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
[TBL] [Abstract][Full Text] [Related]
19. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
Weir GM; Hrytsenko O; Stanford MM; Berinstein NL; Karkada M; Liwski RS; Mansour M
Oncoimmunology; 2014; 3(8):e953407. PubMed ID: 25960932
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
